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S U M M A R Y
Objectives: To determine the diagnostic accuracy, technical beneﬁt, and clinical application of the duplex
reverse transcription-PCR (duplex RT-PCR) assay speciﬁc to bradyzoite (BAG1) and tachyzoite (SAG1)
genes, for diagnosing toxoplasmic encephalitis (TE) in HIV-infected patients, using the US Centers for
Disease Control and Prevention (CDC) recommended diagnostic criteria as the reference standard.
Methods: Advanced HIV-infected individuals with central nervous system opportunistic infections were
enrolled in a prospective study, performed from July 2007 to January 2009; patients were classiﬁed as
TE- or non-TE subjects in accordance with the CDC recommended criteria. Blood and cerebrospinal ﬂuid
samples were assayed by duplex RT-PCR to detect tachyzoite, bradyzoite, both, or none.
Results: A total of 61 advanced AIDS patients were included in the study, eight with TE and 53 as non-TE
subjects. The duplex RT-PCR assay showed high diagnostic accuracy, with 100% speciﬁcity and positive
predictive value, as well as 87.5% sensitivity. Its efﬁcacy reached 98.3%. This diagnostic method was
rapid, needed only moderately skilled technicians, and was four times cheaper than procedures used in
the CDC diagnostic recommendations. It worked very well for blood samples, even after drug treatment
had been started.
Conclusions: The duplex RT-PCR assay is simple and rapid, and provides high efﬁcacy with lower costs
than the reference standard procedures. This is a promising alternative diagnostic tool for TE in HIV/AIDS
individuals, especially in resource-limited settings.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Toxoplasmic encephalitis (TE), a life-threatening disease, is the
most common focal brain lesion in HIV/AIDS individuals. Although
the incidence decreased from 4.0–20.5 to 3.9 cases/100 patient-
years as a result of widely advocated prophylaxis, it has further
decreased dramatically to 1.0 case/100 person-years since the
introduction of highly active antiretroviral therapy (HAART).1–5 It
has been found that approximately 20–40% of patients who are co-
infected with HIV and Toxoplasma gondii develop TE, and 97% of
these cases are as a result of reactivation of a chronic quiescent
infection when CD4 cell counts are <100 cells/mm3,6–9 In such
patients, dormant bradyzoites change into rapidly dividing and
active tachyzoites, causing severe tissue destruction and inﬂam-
mation. Hence, the bradyzoite/tachyzoite stage conversion reac-* Corresponding author. Tel.: +66 2 354 9100 ext. 1830; fax: +66 2 643 5601.
E-mail address: tmymv@mahidol.ac.th (Y. Sukthana).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.12.009tion plays a crucial role as the ﬁrst step in the event, before severe
clinical manifestations subsequently occur.
The deﬁnite diagnosis of TE as recommended by the US Centers
for Disease Control and Prevention (CDC), requires the identiﬁcation
of the organism in a clinical sample. This necessitates a brain biopsy
by stereotactic computed tomography (CT)-guided needle biopsy,
and Toxoplasma tachyzoites are then demonstrated by hematoxylin
and eosin (H&E) staining, for which the sensitivity may be increased
by immunohistochemistry techniques.10 The patient’s condition
and the limitation of experienced pathologists often make these
processes impracticable. For the presumptive diagnosis of clinically
suspected TE cases, the CDC recommended criteria should thus be
applied, i.e., (1) recent onset of clinical features consistent with
generalized and focal neurological abnormalities; (2) suggestive
radiological characteristics on brain imaging of the lesions; and (3)
evidence of chronic T. gondii infection or successful response to anti-
Toxoplasma therapy.8 By using these presumptive diagnostic
criteria, the positive predictive value is achievable in approximately
80%.11 The CDC criteria are thus widely used as the referenceses. Published by Elsevier Ltd. All rights reserved.
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appear as multiple ring-enhanced nodular lesions,12 however
solitary lesions are evident in 14% of cases and mimic primary
cerebral lymphoma, which more commonly presents as a single
mass than toxoplasmosis.13 To differentiate between the two, highly
sophisticated radiological procedures are needed; however these
are costly and their availability is limited, especially in resource-
poor settings. Therefore their diagnostic value is decreased.
We recently developed a duplex reverse transcription PCR
(duplex RT-PCR) assay based on the stage-speciﬁc tachyzoite
(SAG1) and bradyzoite (BAG 1) genes for the detection of
bradyzoite/tachyzoite stage conversion.14 It was found that the
duplex RT-PCR could distinguish between the chronic and acute
stages of Toxoplasma infection. In addition, it was an easy,
sensitive, and reproducible method. We therefore conducted a
prospective study to evaluate the diagnostic sensitivity and
speciﬁcity of the developed duplex RT-PCR assay in HIV/AIDS
patients with TE. Technical beneﬁts and clinical application were
also analyzed and compared to the CDC recommended diagnostic
criteria as the reference standard.
2. Materials and methods
2.1. Patients and selection criteria
This prospective study was carried out with the approval of the
Ethics Review Committee for Research in Human Subjects,
Ministry of Public Health, Thailand (Ref. No. 33/2550). After
obtaining informed consent, patients from a tertiary hospital
setting, the Bamrasnaradura Infectious Disease Institute, Depart-
ment of Disease Control, Ministry of Public Health, were enrolled
consecutively from July 2007 to January 2009. The selection
criteria were: (1) age 18 years, (2) both sexes, (3) advanced HIV
with CD4 counts <200 cells/mm3, and (4) neurological abnormali-
ties at the time of enrollment. Patients were included whether this
was a ﬁrst episode of TE or a relapsed case, and whether or not they
had received prophylaxis. Once the study subject was enrolled,
200 ml of whole blood and cerebrospinal ﬂuid (CSF) samples were
collected on the day of admission; the samples were mixed with
1 ml TRIzol and then kept at 80 8C until use.
Patients were assigned to the TE group when they were
diagnosed as having TE based on the CDC criteria, i.e., (1) signs and
symptoms of central nervous system (CNS) dysfunction, (2)
suggestive lesions on CT or magnetic resonance imaging (MRI),
and (3) seropositivity for T. gondii antibody or a response to anti-
Toxoplasma therapy. The remaining patients, who had neurologi-
cal abnormalities but were not suspected of having TE and who
were without suggestive brain imaging features, as well as being
negative for T. gondii antibody, were assigned to the non-TE group.
2.2. CDC recommended diagnostic criteria
To apply the CDC diagnostic criteria for assignment to the TE or
non-TE groups, all of the study subjects underwent three examina-
tions. The ﬁrst was a physical examination, performed by three
infectious disease specialists looking for any of the following: (1)
generalized cerebral dysfunction, (2) focal signs and symptoms in
the CNS, and (3) psychiatric abnormalities. Presenting neurological
abnormalities suggestive of TE include headache, fever, alteration of
consciousness, confusion, cognitive impairment, hemiparesis, facial
nerve palsy, and convulsions. The second examination involved
brain imaging studies, CT or MRI, evaluating features typical of TE;
this was performed by qualiﬁed radiologists. Features include
multiple nodular, ring-enhanced lesions with edema and mass
effect, as well as lesions occurring in the basal ganglia, thalamus, and
corticomedullary junction.12 The third examination involved thedetection of Toxoplasma IgG antibody by a gold standard dye test at
the reference laboratory unit, the Department of Protozoology,
Faculty of Tropical Medicine, Mahidol University. Pyrimethamine
and sulfadiazine plus folinic acid were given to suspected TE cases
who showed, at the least, either clinical features or laboratory
evidence to strengthen the diagnosis.10
2.3. Duplex RT-PCR assay
In addition to the clinical examination, all blood and CSF
samples were individually subjected to a duplex RT-PCR assay to
determine whether they contained bradyzoites, or tachyzoites, or
both stages, or none. This was carried out by a single specialist who
was blinded to whether the samples came from TE or non-TE cases.
The assay comprised three main steps: nucleic acid extraction,
reverse transcription, and duplex polymerase chain reaction.
Total RNA from collected blood and CSF samples was extracted
using TRIzol reagent (Invitrogen), as previously prescribed.14 All
samples were individually homogenized in 1 ml TRIzol reagent and
the mixture squeezed several times through 20-gauge needles to
thoroughly break up the cells, resulting in a higher RNA yield. Once
extracted, the RNA concentration was measured, RNA integrity
checked, and the sample was then stored at 80 8C until use.
The reverse transcription process was carried out starting with
the generation of cDNA from the extracted RNA. A 20-ml reaction
mixture containing 0.5 mg oligo(dT)-primers and 200 U of
RevertAidTM M-MuL V Reverse Transcriptase (Fermentas) was
incubated at 42 8C for 1 h; the reverse transcriptase enzyme was
then stopped by increasing the temperature to 70 8C for 10 min.
Five microliters of the generated cDNA were used for the
subsequent duplex-PCR reactions.
Two sets of primers were used in this study, as described by
Mahittikorn and colleagues.14 First, speciﬁc to the tachyzoite
(SAG1) gene, the primers 50-GCT GTA ACA TTG AGC TCC TTG ATT
CCT G-30 and 50-CCG GAA CAG TAC TGA TTG TTG TCT TGA G-30were
used to generate a 355-bp product. Second, speciﬁc to the
bradyzoite (BAG1) gene, the primers 50-AGT CGA CAA CGG AGC
CAT CGT TAT C-30 and 50-ACC TTG ATC GTG ACA CGT AGA ACG C-30
were used to generate a 200-bp product and a 637-bp product,
ampliﬁed from cDNA and gDNA, respectively.
The optimized PCR conditions were: a ﬁnal volume of 25 ml,
containing 1.0 U Taq DNA polymerase (Fermentas), 2.5 ml of 10 nM
Tris–HCl pH 8.8, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM of each dNTP,
and 0.18 mM of SAG1 and 0.22 mM BAG1 primers. The temperature
proﬁle (MasterCycler-Gradient, Eppendorf) was: a single denatur-
ation step at 95 8C for 1 min; 40 cycles of 95 8C for 1 min, 62 8C for
1 min, and 72 8C for 1 min; and a ﬁnal extension step at 72 8C for
10 min. All experiments were done in triplicate and included
negative and positive controls. The PCR products were ﬁnally
separated by size on a 1.8% agarose gel and documented with
G:BOX HR (Syngene).
2.4. Data collection and statistical analysis
The following variables were collected from the patient case
record forms (CRF) and recorded: sex, age, duration of HIV
infection, the most recent CD4 counts before samples were taken,
history of treatment for opportunistic infections (OIs), drugs
received including HAART, clinical manifestations, and OIs
diagnosed by clinicians at the Bamrasnaradura Infectious Disease
Institute according to the standard criteria for each OI. Three CDC
recommended criteria were used for the diagnosis of TE.8 For the
results of the duplex RT-PCR, the patient was considered positive
when two or more of three tested samples were positive.
Qualitative variables were described using frequencies and
percentages, while mean and range were used for quantitative
Using CDC criteria: 
TE gro up, n = 7 
During 1-year 
follow-up  
Proven TE cases 
n = 8 
Non-TE cases 
n = 53 
Proven TE 
cases,  n = 1 
Usin g CDC  criter ia: 
Non- TE gro up,  n = 54 Excluded because 
incomplete 
information and 
lack of clinical 
specimens  
n = 9 
Studi ed su bjects  enro lled accor ding  
to selection  cr iteria, n = 70 
Figure 1. Flow diagram of the diagnostic accuracy study.
Y. Sukthana et al. / International Journal of Infectious Diseases 16 (2012) e279–e284 e281variables. The diagnostic accuracy with a measurement of
statistical uncertainty (95% conﬁdence interval (95% CI)) of our
duplex RT-PCR was conducted using the CDC criteria as reference
standard, and the sensitivity, speciﬁcity, and positive and negative
predictive values reported according to the method of DeLong and
colleagues.l5 Technical beneﬁt was measured based on the service
cost in Thailand by time, costs, and skill level required of
technicians for these two diagnostic tools.
3. Results
3.1. Patient characteristics
In total there were 70 HIV-infected patients eligible for our
study. Of these, nine (three from the TE group and six from the non-
TE group) were excluded because of a lack of clinical information
and/or incomplete clinical specimens. Of the remaining 61
patients, seven were assigned to the TE group on admission,
either with a ﬁrst episode or a relapse. One of the 54 cases in the
non-TE group was ﬁrst diagnosed with cryptococcosis, but 10
months later he developed TE-related clinical features and his CT
scan conﬁrmed the diagnosis. Therefore, he was moved into the TE
group. Altogether, there were eight conﬁrmed TE cases, of whichTable 1
Characteristics of study patients in the toxoplasmic encephalitis (TE) and non-toxoplas
Variables 
Matched variables
Male sex, n (%) 
Age, years, mean (min–max) 
CD4 count, cells/mm3, mean  SD 
Positive T. gondii antibody, n (%) 
Opportunistic infections, n (%)
First TE episode 
TE relapse 
Cryptococcal meningitis 
TB 
CMV encephalitis 
Multiple infections 
Duration between anti-toxoplasmic drugs received and sample collection 
SD, standard deviation; TB, tuberculosis; CMV, cytomegalovirus.two were ﬁrst episode and six were relapsed. Fifty-three were non-
TE cases with other CNS opportunistic infections (Figure 1).
In the present study, patients in the TE and non-TE groups were
similar with regard to mean age and the predominance of males
(Table 1), although the TE group was slightly older (mean  SD,
42.6  0.18 vs. 35.4  8.35, p = 0.01) and had a higher percentage of
males (75% vs. 60.4, p = 0.16) than the non-TE group. The mean CD4
count of TE patients was <100 cells/mm3 (mean  SD, 46.5  31.12
cells/mm3), while the control subjects with other OIs had a slightly
higher mean CD4 count (mean  SD, 104.45  111.97 cells/mm3),
however the difference was not statistically signiﬁcant. All eight TE
cases received anti-Toxoplasma treatment before specimen collec-
tion. The interval between the start of therapy and sample collection
was 1 day to 1 year, as shown in Table 1. In the non-TE group,
cryptococcal meningitis was the most common OI found, accounting
for 45.3%, followed by tuberculosis (TB; 15.1%), cytomegalovirus
(CMV) encephalitis (9.4%), and Pneumocystis jiroveci pneumonia (PCP;
3.8%). Mixed infections were found in 12.5% in the TE group and in
34.0% in the non-TE group.
3.2. Diagnostic accuracy of the duplex RT-PCR
Neither SAG1 nor BAG1 was positive among the blood and CSF
samples of the 53 non-TE subjects. Seven out of eight bloodmic encephalitis (non-TE) groups
TE cases n = 8 Non-TE cases n = 53 p-Value
6 (75%) 32 (60.4%) p = 0.16
42.6 (32–55) 35.4 (18–50) p = 0.01
46.5  31.12 104.45  111.97 p = 0.2
5 (62.5%) 3/41 (7.3%)
2 (25%) -
6 (75%) -
2 (25%) 24 (45.3%)
2 (25%) 8 (15.1%)
- 5 (9.4%)
1 (12.5%) 18 (34.0%)
1 day–1 year -
Table 2
Results of blood analysis by duplex RT-PCR compared with the reference standard,
the CDC recommended criteria, to diagnose toxoplasmic encephalitis (TE) and non-
toxoplasmic encephalitis (non-TE)
Diagnosed by reference standard (CDC
recommendation criteria)
TE cases Non-TE cases Total cases
Diagnosed by RT-PCR assay
TE cases 7 0 7
Non-TE cases 1 53 54
Total cases 8 53 61
CDC, US Centers for Disease Control and Prevention.
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(Tables 2 and 3), but none of the CSF samples were positive. The
tachyzoite stage-speciﬁc gene (SAG1) was found in two cases
(patients T39 and T66, Table 3), while the bradyzoite stage-speciﬁc
gene (BAG1) appeared in ﬁve cases (patients T15, T37, T38, T41,
and C32, Table 3).
Table 2 shows the results obtained with the developed RT-PCR
assay in comparison with the CDC recommended criteria. A
receiver operating characteristic (ROC) analysis was performed in
accordance with DeLong et al.15 and revealed 87.5% (95% CI 47.3–
99.7%) sensitivity, 100% (95% CI 93.3–100%) speciﬁcity, 100%
positive predictive value (PPV), 98.1% negative predictive value
(NPV), and 98.3% efﬁcacy for the duplex RT-PCR. In our study, no
CSF specimen was positive by duplex RT-PCR, thus we did not
calculate the diagnostic accuracy.
3.3. Technical beneﬁts of the duplex RT-PCR
Table 4 shows a comparison of the two diagnostic procedures –
CDC criteria and RT-PCR assay – in terms of time, costs, and
technician skill level, based on the service costs in Thailand. With
regard to time taken, it took about 2–6 days to diagnose TE without
therapeutic trial using the CDC criteria, and 16–21 days if a
therapeutic trial was applied, but only 1–2 days were needed for
the RT-PCR assay. The cost was only US$ 50 when TE was diagnosed
by RT-PCR, but it cost US$ 200–340 without a treatment trial and
US$ 900–1840 with a treatment trial if applying the CDC criteria.
Although both procedures need moderate to highly skilled
technicians, a physician was only needed in the application of
the CDC criteria.
4. Discussion
We assessed the diagnostic value of our developed RT-PCR,
which is speciﬁc to the bradyzoite/tachyzoite stage conversion
reaction, to determine whether it could detect a reactivation
process in HIV-infected patients with TE and to determine its
sensitivity, speciﬁcity, PPV, and efﬁcacy when compared to
diagnosis with the CDC criteria. TE patients were compared with
non-TE HIV/AIDS individuals with other CNS OIs. The character-
istics of these two groups were similar in terms of the male gender
predominance (Table 1). Patients who had developed TE were
slightly older than those who had not. This might be because TE
usually develops later than other OIs such as CMV infection and
PCP, which were found in 9.4% and 3.8% of the non-TE group in this
study. Matched variables such as CD4 count indicated a more
profound immunodeﬁciency in the TE group than in the control
group, but this was not statistically signiﬁcant (46.5  31.12 vs.
104.45  111.97, p = 0.2). T. gondii antibody was found in both groups.
Although it was found in only 7.3% of the non-TE group, these patients
are high-risk subjects who urgently need primary prophylaxis in
order to prevent a ﬁrst episode of TE reactivation.
Table 4
Comparison of the technical beneﬁt of the two diagnostic procedures – CDC criteria and RT-PCR – based on the estimated service costs in Thailand
Technical beneﬁt Diagnostic procedure
CDC criteria RT-PCR assay
Clinical features Brain imaging Serology Response to
treatment
Total
Time (days/case) 0.5 0.5–5a 1 14 2–6b
16–21c
1–2
Cost (US$/case) 20–60 160–250 20–30 700–1500 200–340b
900–1840c
50
Technician
skill level
Moderate to highly
skilled physician
Moderately skilled
technician
Moderately
skilled
technician
Skilled physician Moderate to highly
skilled physician and
technician
Moderate to highly
skilled technician
CDC, US Centers for Disease Control and Prevention.
a Time for brain imaging, including the time taken to perform the imaging and the schedule of service queue.
b Total time and cost for CDC diagnostic criteria without treatment trial.
c Total time and cost for CDC diagnostic criteria with treatment trial.
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organism in a clinical specimen, which is often impracticable. The
CDC recommended criteria, by a combination of clinical relevance
with CNS dysfunction, suggestive characteristics on brain imaging,
and evidence of latent T. gondii infection or response to therapy, are
alternative presumptively diagnostic procedures currently in use
in clinical practice.8,10 On brain imaging, most TE lesions are
multiple and located in the basal ganglia, thalamus, and
corticomedullary junction,12 but these are not pathognomonic
ﬁndings. MRI is more sensitive than CT; Weenink and colleagues
reported a TE patient who showed a normal contrast-enhanced CT
scan, but MRI showed typical abnormalities in the basal ganglia.16
TE usually appears as multiple nodular or ring-enhanced lesions
with edema and mass effect, but 14% of cases show a solitary lesion
and these need to be differentiated from CNS lymphoma, which
more commonly presents as a single mass than toxoplasmosis.13
Although several techniques such as diffusion weighted imaging,
single-photon emission CT (SPECT), and positron-emission tomog-
raphy (PET) could provide a more precise diagnosis,8,13 they are
costly and not widely available, especially in resource-limited
settings.8 In addition, Toxoplasma IgG antibody in HIV/AIDS
patients who develop TE reactivation always presents with a low
titer, and in 3–5% of patients the antibody is negative.17 These
factors make a presumptive diagnosis of TE more difﬁcult, and
result in an 80% probability of the patient having the disease (PPV)
when TE is the diagnosis made by CDC criteria.11 Our RT-PCR assay
when used as another diagnostic procedure, provided a 100% PPV
and speciﬁcity, with a high sensitivity of 87.5% (95% CI 47.3–99.7)
using blood specimens. It took only 1–2 working days to perform
by a moderately skilled laboratory technician, with the costs 4
times less than those incurred using the CDC criteria without
therapeutic treatment, and less still when the therapeutic
treatment criterion was included (Table 4). Nevertheless, specimen
collections need a speciﬁc solution (TRIzol) for preserving the
mRNA, which is not stable, and there is the need to differentiate
between the bradyzoite (BAG1) and tachyzoite (SAG1) genes of T.
gondii.
In the present study, SAG1 was found in two cases (patients T39
and T66), indicating an active tachyzoite stage that should be
compatible with an acute reactivation process. The other ﬁve cases
revealed bradyzoites (BAG1), consistent with a chronic infection
phase (Table 2). The case record forms of these patients were
carefully reviewed and it was found that only one patient (T66)
showed an active clinical reactivation process. He was a ﬁrst TE
episode case, and he had received anti-Toxoplasma drugs only 4
days prior to specimen collection; tachyzoites thus still remained
to be recovered. Case T38 was another new TE reactivation case,but the duplex RT-PCR showed BAG1, which might be because he
had received a standard anti-Toxoplasma combination (pyrimeth-
amine and sulfadiazine plus folinic acid) for 2 weeks before blood
collection. The mechanisms that regulate conversion of tachyzoite
into bradyzoites are predominant.14,18 Tachyzoites were thus
transforming into bradyzoites, which are resistant to all drug
regimens and hide in a parasitophorous vacuole without any
recognition by the host’s immune system.19 Another case (T39)
with SAG1 was a TE relapse, twice, who had received trimetho-
prim–sulfamethoxazole (TMP–SMZ) plus folinic acid treatment
from another hospital, maintained as a secondary prophylaxis for 1
month. Finding SAG1 in that case might be because TMP–SMZ,
although an alternative treatment for TE, is effective at 85.5% when
compared with the standard regimen.20
The limitations of the present study were: (1) the number of TE
cases was small due to its decreased incidence since the
introduction of HAART. (2) All TE study subjects were treated
before specimen collection with a duration of 1 day to 1 year (Table
1), and the majority of these were on secondary prophylaxis which
affected the speciﬁc stage of the parasite resulting in more BAG1
than SAG1. This might be misleading when evaluating and
interpreting the diagnostic value of the RT-PCR. (3) No CSF
specimen was positive by duplex RT-PCR. Indeed, it has been
shown by other researchers that CSF-PCR may have disappointing
results, especially when the specimen is taken after treatment has
started.8,10,17 To overcome this limitation, the developed duplex
RT-PCR should be applied only on blood samples, not CSF, and
before initiating drug therapy. However, this is an advantage
because obtaining blood is actually much easier than obtaining
CSF.
PCR detection of Toxoplasma in blood specimens has been
proven to be useful, but with wide variations in sensitivity.8,10,17 In
clinical practice, treatment is often initiated before the sample is
taken for PCR. Hence the detection rate is dramatically lowered.21
Bastien showed the sensitivity of PCR testing in HIV-infected
subjects who developed episodes of TE without antiparasitic
treatment to be 86.6% for blood samples and 60% for CSF, but only
25% and 16.7%, respectively, in subjects receiving speciﬁc
treatment or prophylaxis against PCP.22 Our initial aim was the
use of the duplex RT-PCR to differentiate between the bradyzoite
and tachyzoite stages, which indicates an acute reactivation or
chronic phase. Since all studied subjects were treated before the
assay application, this purpose was thus less highlighted. Even
then, the results of both PPV and speciﬁcity were still 100%, with a
high sensitivity at 87.5% when compared with the conventional
presumptive diagnostic procedures recommended by the CDC. The
present study showed higher sensitivity and speciﬁcity than those
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the duplex RT-PCR on blood samples.21,23,24 Moreover, the
technique is rapid, easy to perform, and has the beneﬁt of
affordable cost, making it much cheaper than the CDC criteria
procedures. In fact, the cost was only a little higher than that of
conventional PCR, but it yielded much higher results. The
developed RT-PCR could detect the parasite in the blood of
patients who had continued to receive therapy. Interestingly, one
patient (C32) was not suspected of having TE but was diagnosed
with cryptococcal meningitis at the time of enrollment. His duplex
RT-PCR result showed him to be BAG1-positive (Table 2) with
negative Toxoplasma antibody. Ten months later he developed TE.
This example, even as a single case, might prove the prognostic
capability of the duplex RT-PCR in predicting TE reactivation.
In conclusion, this novel, duplex RT-PCR technique is proven to
have promising diagnostic value in terms of its high speciﬁcity,
sensitivity, and efﬁcacy in the diagnosis of TE in HIV/AIDS patients,
even in treated ones. The RT-PCR gives an excellent yield with
blood samples, and it is easier to manage suspected TE cases using
blood rather than CSF specimens. In addition, it is also useful for
the diagnosis of extracerebral toxoplasmosis in AIDS patients, in
whom the clinical and radiological features are more difﬁcult to
interpret. Speciﬁcs of the bradyzoite/tachyzoite stage obtained
from such assays will be useful for physicians in planning the
appropriate prophylaxis or treatment in the high-risk population
who are co-infected with HIV and T. gondii. Although serial
specimens from AIDS patients are necessary for further evaluation
of this technique, particularly from those who have TE with and
without speciﬁc treatment, it can still be recommended for use as
an alternative presumptive diagnostic procedure, especially in
resource-poor settings.
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